Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Neovascular Age Related Macular Degeneration
Interventions
DRUG

Squalamine lactate

Ophthalmic solution 0.2%

DRUG

Vehicle control

Ophthalmic solution vehicle control

Trial Locations (20)

10021

Macula Care, New York

17011

PA Retina, Camp Hill

21237

Elman Retina, Baltimore

21740

Cumberland Valley Retina Consultants, Hagerstown

33426

Florida Eye Microsurgical Institute Inc., Boynton Beach

33907

Retina Health Center, Fort Myers

37203

TN Retina, Nashville

44122

Retina Associates of Cleveland, Cleveland

46290

Midwest Eye Institute, Indianapolis

48073

Vision Research Foundation, Royal Oak

49546

Vision Research Foundation, Grand Rapids

49686

Vision Research Foundation, Traverse City

53705

University of Wisconsin, Madison

78240

Medical Center Ophthalmology Associates, San Antonio

80401

Colorado Retina, Golden

85710

Retina Associates SW, Tucson

90211

Retina-Vitreous Associates, Beverly Hilss

93309

California Retinal Consultants, Bakersfield

02114

Ophthalmic Consultants of Boston, Boston

08901

Total Practice Management, New Brunswick

Sponsors
All Listed Sponsors
lead

Ohr Pharmaceutical Inc.

INDUSTRY